Cynthia Brown, MD
Pulmonary Disease · Indianapolis, INNPI 1700923752
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,560 of the $8,884 with a category attached, or 85.1%. Boehringer Ingelheim accounts for 67.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $5,919 and has fallen 97.1% since, to $171 in 2025.
Across 17 payments — averaging $522.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- Vertex$3K
- Baxter Healthcare$24
- Jazz Pharmaceuticals Inc.$18
- AbbVie$13
Across 57 payments — averaging $127,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$5.4M
- Vertex$1.9M
- AbbVie$3K
- Vivus LLC$719
What the payments were for
- Consulting fees$7,56085%
- Travel & lodging$91210%
- Food & beverage$4125%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $5,992 |
| Vertex | 5 | $2,837 |
| Baxter Healthcare | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| AbbVie | 1 | $13 |
How this compares
$8,884 in reported general payments places this provider in the 75th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 105 | $2,786,994 |
| PertzyeLipase/Protease/Amylase | 32 | $152,918 |
| ZenpepLipase/Protease/Amylase | 20 | $111,866 |
| CreonLipase/Protease/Amylase | 21 | $105,432 |
| Dupixent PenDupilumab | 16 | $56,859 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $51,274 |
| Spiriva RespimatTiotropium Bromide | 14 | $10,426 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,369 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $7,355 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $7,329 |
| XareltoRivaroxaban | 13 | $7,113 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,040 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,653 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,023 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $3,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $2,837 | $2,786,994105 claims |
| AbbVieCreon | $13 | $105,43221 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $5,992 | $17,46627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Indianapolis
- Gary ZalogaIndianapolis$79K
- Abboud KawakIndianapolis$68K
- Ryan LogueIndianapolis$30K
- George RubeizIndianapolis$24K
- Roberto MachadoIndianapolis$22K
- Rajat NarangIndianapolis$17K
- Michael DuncanIndianapolis$16K
- Marcus TielkerIndianapolis$11K
- Michael SnyderIndianapolis$9K
- Jorge Morales EstrellaIndianapolis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.